First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

NCT04858269 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Head Neck Cancer
Metastatic Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma
Oropharynx Squamous Cell Carcinoma
Hypopharynx Squamous Cell Carcinoma
Larynx Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]